Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.
Also called NCT01363661
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 165 participants
- Sponsor
- Therabel Pharma SA/NV
- Registry
-
NCT01363661 -
2011-000190-31
-
- Other papers using this trial's data
- Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: results of the MEDCOR trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belgium
- Registry status
- Completed
Technical summary
Registry record NCT01363661. Randomized; triple masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2014-09-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris
- Acronym
- MEDCOR
- Condition
- Stable Angina Pectoris
- Condition
- Atherosclerosis
- Intervention (Drug)
- Coruno
- Intervention (Drug)
- Placebo
- Lead sponsor
- Therabel Pharma SA/NV
Record details
- Record id
cardio:ct-nct01363661- Content hash
36052200523ed6408f283241fe95a6a162c6ba494fe9e7a57ad93ec5a67854c2